OncoPro Tumoroid Cell Lines

3D cancer research starts with quality cancer organoid cell lines

Kick-off your 3D cancer research workflow with our Gibco OncoPro Tumoroid Cell Lines. Also referred to as cancer organoid cell lines, these models are established from primary patient tissues and have been fully characterized. Thermo Fisher Scientific and Discovery Life Science (DLS) have partnered to broaden the availability of high-quality, culture-ready, patient-specific tumoroid cell lines and services across a wider range of cancer indications. DLS will now offer tumoroid cell lines that have been derived and expanded in Gibco OncoPro Tumoroid Culture Medium. This medium has been specifically formulated to support the optimal growth of tumoroid cell lines.

When cultured in OncoPro Tumoroid Culture Medium, OncoPro Tumoroid Cell Lines help support quality 3D cancer research since these lines are:

Biologically relevant—preferential expansion of patient-derived cancer cells from diverse cancer indications
Stable—demonstrated to maintain donor-specific phenotype and genotype in long-term culture
Scalable—compatible with a readily-scalable suspension culture method

Available OncoPro Tumoroid Cell Lines

Tumoroid line	Diagnosis - Stage	Tumor site	Race Sex, Age	Height (in), Weight (lb)	Treatment status
HuCo031721	Colorectal adenocarcinoma - IIA	Transverse colon	White Male, 82	70", 260 lb	Pre-Treatment
HuCo111622	Colorectal adenocarcinoma - IIA	Rectum	White Female, 70	63", 215 lb	Pre-Treatment
HuCo083123	Colorectal adenocarcinoma - IIIC	Rectosigmoid	White Male, 46	70", 248 lb	Pre-Treatment
HuCo090123	Poorly differentiated adenocarcinoma - IIA	Colon	African-American Female, 90	63", 138 lb	Pre-Treatment
HuCo100523	Colorectal adenocarcinoma - IIA	Ascending colon	White Female, 85	62", 148 lb	Pre-Treatment
HuCo052121	Colorectal adenocarcinoma - IIA	Rectum	White Female, 46	60", 154 lb	Pre-Treatment
HuCo1044	Colorectal adenocarcinoma - IIB	Transverse colon	White Female, 80	61", 343 lb	Pre-Treatment
HuCo3209	Colorectal adenocarcinoma - I	Sigmoid colon	White Female, 59	67", 176 lb	Pre-Treatment
HuCo021320	Colorectal adenocarcinoma - IVC	Colon	White Female, 58	65", 176 lb	Pre-Treatment
HuLu051421	NSCLC, Squamous cell carcinoma - IA3	Middle lobe of lung	White Male, 63	75", 209 lb	Pre-Treatment
HuLu051921	NSCLC, Large cell carcinoma - IIA	Upper lobe of lung	White Female, 69	67", 169 lb	Pre-Treatment
HuBr102622	Invasive ductal carcinoma, ductal carcinoma in situ present - IA	Breast	White Female, 56	63", 131 lb	Pre-Treatment
HuEn061022	Endometrioid carcinoma - IA	Endometrium	White Female, 67	65", 162 lb	Pre-Treatment
HuEn070722	Dedifferentiated carcinoma - IIIC1	Endometrium, lower uterine segment	White Female, 76	66", 272 lb	Pre-Treatment
HuEn041521	Endometrioid carcinoma - IIIC1	Endometrium	White Female, 78	60", 189 lb	Pre-Treatment
HuEn022222	Endometrioid carcinoma - IA	Endometrium	White Female, 58	62", 150 lb	Pre-Treatment
HuEn033122	Endometrioid carcinoma - IA	Endometrium	White Female, 59	64", 200 lb	Pre-Treatment

Complete the inquiry form below to request additional information or learn how to purchase available tumoroid cell lines from Discovery Life Sciences.

Submit inquiry

Tumoroid cell line data

Explore relevant data that demonstrate the quality and consistency of OncoPro Tumoroid Cell Lines. In-depth characterization data is available for each tumoroid cell line upon request by completing an inquiry form.

Biological relevance of tumoroid cell lines

Figure 1. Tumoroid cell lines preserve donor-specific mutations. Unique genomic mutations are preserved between primary tumors and established tumoroid cultures. Next-generation sequencing (Oncomine Comprehensive Assay v3) was used to identify single-base substitutions (bar graphs), oncogenic mutations, and copy number variations (heat map).

Stability of tumoroid lines

data compilation from cell growth and gene expression studies

Figure 2. OncoPro Tumoroid Cell Lines maintain major characteristics during long-term culture in OncoPro Tumoroid Culture Medium. (A) Cumulative population doubling (PD) was measured by cell counts at each passage. Tumoroid lines were recovered from cryopreservation at the beginning of this experiment (day 0), and additional cryopreservation and recovery points are indicated by arrows for each culture. (B) Representative images of tumoroid morphology before and after prolonged culture. (C) Correlation of germline and somatic single nucleotide variations (SNVs) between early and later passage tumoroid cultures. Each dot represents the variant allelic frequency (VAF) for one genetic locus covered by the Oncomine Comprehensive Assay v3. (D) Principal component analysis of tumoroid transcriptomes demonstrates that tumoroids cluster by donor rather than by passage. (E) Differential gene expression analysis of early versus late passage tumoroids reveals a modest number of differentially expressed genes (DEGs) at fold change >2 and false discovery rate (FDR) <0.05. Gene ontology analysis revealed a few significantly enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways (FDR <0.05) between early and late passage tumoroid cultures; the top 10 results are shown.

Scalability of tumoroid lines

Figure 3. Tumoroid lines grow consistently in an easy-to-use, scalable format.(A) Expansion rates of tumoroids in suspension culture in OncoPro medium. Number of cells counted after thawing from cryopreservation (day 0) and at each passage. (B) Individual samples have consistent growth rates and can typically generate 100 million viable cells within 30 or 60 days.